Logo

LGVN

Longeveron Inc.

LGVN

Longeveron Inc. • NASDAQ
$0.66 ▲ 2.50% (+0.02)
Market Cap $14.17 M
52w High $2.24
52w Low $0.59
Dividend Yield 0%
P/E -0.68
Volume 343.12K
Outstanding Shares 21.35M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $137K ▼ $7.435M ▲ $-7.221M ▼ -5.271K% ▼ $-0.39 ▼ $-6.957M ▼
Q2-2025 $316K ▼ $5.543M ▲ $-5.028M ▼ -1.591K% ▼ $-0.33 ▲ $-4.765M ▼
Q1-2025 $381K ▼ $5.456M ▲ $-5.011M ▼ -1.315K% ▼ $-0.34 ▼ $-4.76M ▼
Q4-2024 $603K ▼ $4.811M ▼ $-4.081M ▲ -676.783% ▼ $-0.27 ▲ $-4.039M ▲
Q3-2024 $773K $5.331M $-4.419M -571.669% $-0.34 $-4.414M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $9.244M ▼ $15.557M ▼ $5.591M ▲ $9.966M ▼
Q2-2025 $10.334M ▼ $16.749M ▼ $4.093M ▲ $12.656M ▼
Q1-2025 $14.327M ▼ $20.848M ▼ $3.69M ▲ $17.158M ▼
Q4-2024 $19.232M ▼ $25.558M ▼ $3.671M ▼ $21.887M ▼
Q3-2024 $22.778M $29.909M $4.282M $25.627M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.221M ▼ $-5.055M ▼ $-118K ▲ $4.083M ▲ $-1.09M ▲ $-5.112M ▼
Q2-2025 $-5.028M ▼ $-3.597M ▲ $-263K ▼ $-133K ▼ $-3.993M ▲ $-3.758M ▲
Q1-2025 $-5.011M ▼ $-4.697M ▼ $-150K ▼ $-58K ▼ $-4.905M ▼ $-4.724M ▼
Q4-2024 $-4.081M ▲ $-3.373M ▼ $-123K ▲ $-50K ▼ $-3.546M ▼ $-3.386M ▼
Q3-2024 $-4.419M $-2.843M $-478K $13.724M $10.403M $-3.273M

Five-Year Company Overview

Income Statement

Income Statement Longeveron is still essentially a pre‑revenue biotech. The company has not yet built a recurring sales base, and its results are driven almost entirely by research and development and overhead costs. Losses have been relatively steady over the past several years, which signals a focused but ongoing spend to advance the pipeline rather than a commercial operation. The per‑share loss looks large mainly because of share consolidation, not because cash spending has suddenly exploded. Overall, the income statement reflects an early clinical-stage company: high scientific ambition, but no commercial payoff yet.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small pool of assets, most of which is cash or cash-like. There is no reported debt, which removes interest burden but also suggests that equity raises and partnerships are the primary funding tools. Shareholders’ equity is modest and has drifted down over time, showing that cumulative losses are eating into the capital base. This leaves the company financially lean and likely sensitive to market conditions when it needs fresh funding for trials.

Cash Flow

Cash Flow Cash flows are negative, as you would expect from a clinical-stage biotech. The company consistently spends more cash on operations than it brings in, and there is practically no spending on long-lived assets or equipment, so free cash flow is effectively the same as operating cash flow. The burn rate looks controlled rather than explosive, but with no operating revenue, the business depends on raising external capital or signing partnerships to keep funding development. The key question is not whether cash is going out, but how long the existing cash can sustain planned studies.

Competitive Edge

Competitive Edge Longeveron competes in a crowded and fast-evolving cell therapy and neurodegenerative disease space, but it has carved out some differentiators. Its lead product, Lomecel‑B, is an “off‑the‑shelf” stem cell therapy targeting aging-related diseases and rare pediatric heart conditions, which is a somewhat distinct angle versus many single-target drugs. Regulatory designations from the FDA for several programs give it potential speed and support advantages. In-house manufacturing and the move into contract development and manufacturing add another layer of capability and potential revenue. Still, the company is early-stage, with no approved products yet, and is going up against much larger and better-funded players, especially in Alzheimer’s, so its competitive position is more about future potential than proven market strength.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Longeveron’s story. The company is betting on a single, versatile stem cell platform, Lomecel‑B, that it is pushing into several different diseases: a rare pediatric heart defect (HLHS), Alzheimer’s disease, aging-related frailty, and pediatric cardiomyopathy. The science emphasizes broad anti-inflammatory and regenerative effects, which, if successful, could support multiple indications off the same technology. Their proprietary manufacturing process and regulatory designations support this R&D engine. However, the pipeline is still in clinical development, with key readouts and pivotal trials several years away and heavily dependent on sufficient funding. This means the scientific upside is significant but paired with high clinical and financing risk.

Summary

Overall, Longeveron looks like a classic early-stage biotech: scientifically ambitious, financially small, and pre‑revenue. The financials show steady losses, a thin but debt‑free balance sheet, and ongoing cash burn that will likely require additional capital or partnerships. On the other hand, the company holds a focused, differentiated cell therapy platform with favorable regulatory designations and an emerging manufacturing services business that could diversify its income over time. The central tension is straightforward: promising technology and well-defined clinical milestones versus limited financial resources, long timelines, and typical biotech development risk. Outcomes will hinge on trial results, execution of the CDMO strategy, and the company’s ability to secure funding on reasonable terms.

NEWS

November 19, 2025 · 9:15 AM UTC

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Read more

November 12, 2025 · 9:05 AM UTC

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Read more

October 27, 2025 · 9:15 AM UTC

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Read more

October 6, 2025 · 9:15 AM UTC

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Read more

September 22, 2025 · 9:15 AM UTC

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Read more